Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (NASDAQ: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 566 restricted stock units (RSUs) to two new employees as of May 31, 2025. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with one-third vesting annually on the grant date anniversary. Full vesting acceleration applies if employment terminates for good reason or without cause within one year of a change in control event.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's senior management team will engage in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York. Investors and interested parties can access a live webcast of the presentation through the company's investor relations website, with a replay available after the event.

Karyopharm Therapeutics (KPTI) will present new data on selinexor in treating myelofibrosis at the 2025 EHA Annual Meeting. The Phase 2 XPORT-MF-035 trial results showed promising outcomes in hard-to-treat patients:

- 67% of selinexor-treated patients achieved ≥25% spleen volume reduction vs 38% in physician's choice (PC) group - 33% achieved ≥35% spleen volume reduction vs 13% in PC group - Higher mean hemoglobin levels and lower transfusion rates - Greater reductions in key cytokines (IL-6, IL-8, TNFa, hepcidin)

The trial involved 24 patients (12 per arm), with 6 crossing over from PC to selinexor. Common side effects included decreased weight (50%), anemia (25%), and nausea (33%). Notably, no treatment discontinuations occurred in the selinexor arm due to adverse events.

Karyopharm Therapeutics (KPTI) reported Q1 2025 financial results and clinical progress. Total revenue was $30.0M, with U.S. XPOVIO net product revenue of $21.1M, down from $26.0M in Q1 2024 due to a $5.0M increase in product return reserve. The company reaffirmed its 2025 guidance of $140-155M in total revenue. Key clinical developments include: The Phase 3 SENTRY trial in myelofibrosis passed its futility analysis and is ~80% enrolled, with completion expected in June/July 2025. New Phase 2 data showed promising results for selinexor in treating myelofibrosis, with 67% of patients achieving ≥25% spleen volume reduction. The company reported a net loss of $23.5M ($2.77 per share) and had $70.3M in cash as of March 31, 2025. Management is exploring alternatives to extend cash runway beyond early Q4 2025.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025. The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss financial results and provide company updates.

Investors can access the conference call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live audio webcast with accompanying slides will be available on the company's investor relations website, with an archived version accessible approximately two hours after the event.

Karyopharm Therapeutics (NASDAQ: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 983 restricted stock units (RSUs) to two newly-hired employees as inducement awards. The RSUs were granted on April 30, 2025, under the company's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over a three-year period, with 33 1/3% vesting annually on the grant date anniversary, contingent on continued employment. In case of a change in control event, the RSUs will fully vest if the employee is terminated for "good reason" or without "cause" within one year of the event.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 1,850 restricted stock units (RSUs) to two newly-hired employees as of March 31, 2025.

The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting on each anniversary of the Grant Date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements. Additionally, the RSUs include an acceleration clause allowing immediate full vesting if employment is terminated for 'good reason' or without 'cause' within one year of a change in control event.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 3,316 restricted stock units (RSUs) to five newly-hired employees as of February 28, 2025.

The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting on each anniversary of the Grant Date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.

The RSUs include an acceleration clause that allows for immediate full vesting if the employee's employment is terminated for 'good reason' or without 'cause' within one year of a change in control event.

Karyopharm Therapeutics (KPTI) has announced a 1-for-15 reverse stock split effective February 25, 2025, at 5:00 p.m. Eastern Time. The split aims to increase the per-share market price to regain compliance with Nasdaq's minimum bid price requirement.

The stock will begin trading on a split-adjusted basis on February 26, 2025. The reverse split will reduce outstanding shares from approximately 126.2 million to 8.4 million, and authorized shares from 800 million to 53.3 million. Proportionate adjustments will be made to equity incentive plans, outstanding equity awards, warrants, and convertible notes.

No fractional shares will be issued; stockholders will receive cash payments instead. Computershare Trust Company is acting as the exchange agent, and stockholders holding shares electronically need not take action to receive post-split shares.